Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Feb 09, 2022 11:51am
118 Views
Post# 34412764

RE:Building anticipation to achieve an optimal result

RE:Building anticipation to achieve an optimal resultDr Rothenberg is also a Board Member of Surrozen ,and Tngo THreapeutics ,and Aulos Science ,,,
Aulos has what appears to be a very disruptive approach to treating cancer...

While I think its great that he is advising THTX I think that coming to the conclusion that he came on board because  he sees certainty of  success in TH 1902 is far fetch....He is getting paid for his consulting work and probably a friend pf Paul

I dont think Rothenburgh could have seen any concrete evidence of success when he joined many months ago when there were just a handful of patients enrolled in the trial....
Nice to have him as part of the consultants but I fail to see how this can be considered as sign of success.....


SPCEO1 wrote: On the presumption that there is something noteworthy in the phase 1a results, one way TH could signal that and build some anticipation among investors for those results would be to note that Dr. Rothenberg will be participating on their 4Q and full year results conference call when they send out the press release announcing the date of the release and call. 

Of course, what they have to share might not justify his presence on the call but let's hope it does. 


<< Previous
Bullboard Posts
Next >>